A springboard for growth

In 2018, we decided that Zhangjiang was going to be our headquarters for drug R&D because there was a great pool of technology and biotech talents here. In the Shanghai FTZ, there are more pharmaceutical R&D talents. I witnessed the transformation of China over the past 20 years. Setting up our R&D center in Zhangjiang was probably one of the best decisions we have ever made.

|<< Previous 1 2 3 4 5 6 7 8 9 10 11